New drug combo aims to boost immune attack on Hard-to-Treat cancers

NCT ID NCT05061628

Completed Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called JS006, either by itself or combined with another drug (toripalimab), in people with advanced tumors who have no standard treatment options left. The goal is to see if the combination is safe and tolerable, and to find the best dose for future studies. The study enrolls adults aged 18 to 75 with certain types of advanced cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS006 (anti-TIGIT antibody) and toripalimab (anti-PD-1 antibody)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced tumors who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial with a small number of participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TUMORS

Contacts and locations

Show contact details

Locations

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.